The Future of IPRs & Bio-Pharmaceutical Innovation from The Global South
1. The Future of IPRs &
Bio-Pharmaceutical Innovation from
The Global South
Chirantan Chatterjee
IIMA & Hoover Institution, Stanford University
www.chirantanchatterjee.com
Changing Nature of Innovation Conference
Ahmedabad University and CTIER
May 2021
4. Why Is it that We are Not generating New Antibiotics?
5. Some Answers from a Field Trip in Summer 2007-2008
- Agglomeration Economies.
- Where is the Scientist-Entrepreneur? (Bayh
Dole Act & Pasteur’s Quadrant).
- Even pre-Covid no Patient Venture Capital.
- Human Capital Issues.
- An extinct taste for biology while focusing on
chemistry in the last 5 decades.
- Regulatory flipflops & flight of entrepreneurs
to locations like Singapore.
- Other locations rising (S-Korea, Bangladesh
among others).
- India and perhaps global south, more and more
an incrementally innovative society (than a
radically innovative society).
- Services & tech innovation takes precedence
over a life-science economy.
6. Where to Next for the Industry?
- Biosimilars (requires science, clinical trials,
regulation)
- Preventive Innovation than Therapeutic
Innovation (Medical Devices startups like
Janacare, Xcyton Diagnostics, Achira et al.)
- Drug Repurposing (Beyond Lopinavir).
- R&D versus non R&D Alliances (the Roche-Cipla
efforts).
- Structural Shifts in Innovation Ecosystem
Required
- Taking advantage of the mRNA Disruption as
other countries catch up.
- Forming R&D Consortiums ala the Japanese?
- Differding, E. (2017). The Drug Discovery and
Development Industry in India—Two Decades of
Proprietary Small‐Molecule R&D.
ChemMedChem, 12(11), 786-818.
15. Thank You - Health & Wealth - Tough New World & Trade-offs Ahead..
■ “There is nothing I fear more than
waking up without a program that will
help me bring a little happiness to
those with no resources, those who are
poor, illiterate, and ridden with
terminal disease.” - Nelson Mandela.